152 related articles for article (PubMed ID: 15293352)
1. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.
Boyd M; Mairs RJ; Keith WN; Ross SC; Welsh P; Akabani G; Owens J; Vaidyanathan G; Carruthers R; Dorrens J; Zalutsky MR
J Gene Med; 2004 Aug; 6(8):937-47. PubMed ID: 15293352
[TBL] [Abstract][Full Text] [Related]
2. Expression in UVW glioma cells of the noradrenaline transporter gene, driven by the telomerase RNA promoter, induces active uptake of [131I]MIBG and clonogenic cell kill.
Boyd M; Mairs RJ; Mairs SC; Wilson L; Livingstone A; Cunningham SH; Brown MM; Quigg M; Keith WN
Oncogene; 2001 Nov; 20(53):7804-8. PubMed ID: 11753659
[TBL] [Abstract][Full Text] [Related]
3. A gene therapy/targeted radiotherapy strategy for radiation cell kill by.
Boyd M; Mairs RJ; Cunningham SH; Mairs SC; McCluskey A; Livingstone A; Stevenson K; Brown MM; Wilson L; Carlin S; Wheldon TE
J Gene Med; 2001; 3(2):165-72. PubMed ID: 11318115
[TBL] [Abstract][Full Text] [Related]
4. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
5. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
Mairs RJ; Ross SC; McCluskey AG; Boyd M
J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
[TBL] [Abstract][Full Text] [Related]
6. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate.
Fullerton NE; Boyd M; Mairs RJ; Keith WN; Alderwish O; Brown MM; Livingstone A; Kirk D
Prostate Cancer Prostatic Dis; 2004; 7(4):355-63. PubMed ID: 15477875
[TBL] [Abstract][Full Text] [Related]
7. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.
Fullerton NE; Mairs RJ; Kirk D; Keith WN; Carruthers R; McCluskey AG; Brown M; Wilson L; Boyd M
Eur Urol; 2005 Feb; 47(2):250-6. PubMed ID: 15661422
[TBL] [Abstract][Full Text] [Related]
8. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
[TBL] [Abstract][Full Text] [Related]
9. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
[TBL] [Abstract][Full Text] [Related]
10. Transfectant mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy.
Boyd M; Mairs SC; Stevenson K; Livingstone A; Clark AM; Ross SC; Mairs RJ
J Gene Med; 2002; 4(5):567-76. PubMed ID: 12221650
[TBL] [Abstract][Full Text] [Related]
11. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
12. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Kong BH; Song Y; Ma DX; Qu X; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
[TBL] [Abstract][Full Text] [Related]
13. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.
Plumb JA; Bilsland A; Kakani R; Zhao J; Glasspool RM; Knox RJ; Evans TR; Keith WN
Oncogene; 2001 Nov; 20(53):7797-803. PubMed ID: 11753658
[TBL] [Abstract][Full Text] [Related]
14. [Cloning of human telomerase reverse transcriptase promoter for targeted cancer therapy].
Li F; Tan XH; Peng XJ; Cai HB; Hu DR
Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):207-11. PubMed ID: 15699008
[TBL] [Abstract][Full Text] [Related]
15. [Anti-tumor effect of suicide gene therapy using chimeric promoter plus radiotherapy on cancer cell lines].
Sun WJ; Xiong J; Wang WF; Liao ZK; Zhou FX; Zhou YF
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):245-50. PubMed ID: 21575492
[TBL] [Abstract][Full Text] [Related]
16. Radio-activation of hTERT promoter in larynx squamous carcinoma cells: an 'indirected-activator' strategy in radio-gene-therapy.
Liao ZK; Zhou FX; Luo ZG; Zhang WJ; Xiong J; Bao J; Han G; Zhang MS; Xie CH; Zhou YF
Oncol Rep; 2008 Jan; 19(1):281-6. PubMed ID: 18097608
[TBL] [Abstract][Full Text] [Related]
17. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS
J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833
[TBL] [Abstract][Full Text] [Related]
19. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
Mairs RJ; Boyd M
Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
[TBL] [Abstract][Full Text] [Related]
20. Gene manipulation to enhance MIBG-targeted radionuclide therapy.
Mairs RJ; Fullerton NE; Cosimo E; Boyd M
Nucl Med Biol; 2005 Oct; 32(7):749-53. PubMed ID: 16243651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
